1. This article presents a CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors.
2. The authors of the article are K. Tang, X. Zhang, J. Yin, W. Pan, Y. Li, N. Li and B. Tang
3. The article has been accepted for publication in Chemical Communications (RSC Publishing).
The trustworthiness and reliability of this article is high as it has been accepted for publication in Chemical Communications (RSC Publishing), which is a reputable journal with rigorous peer review processes in place to ensure that only quality research is published in its pages. The authors of the article are all experienced researchers in the field of cancer immunotherapy, which adds to the credibility of their work and findings presented in the paper. Furthermore, the article does not appear to contain any promotional content or partiality towards any particular viewpoint or opinion on cancer immunotherapy strategies; instead it provides an objective overview of the potential benefits of using a CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors.
The article does not appear to be missing any points of consideration or evidence for its claims made; instead it provides a comprehensive overview of the potential benefits associated with this type of therapy as well as outlining possible risks that should be taken into account when considering such treatments. Additionally, there does not appear to be any one-sided reporting or unsupported claims present within the paper; instead it provides an unbiased overview of both sides of the argument surrounding this type of therapy and presents both sides equally without favouring either side over another.